Please login to the form below
Celgene wins expanded EU approval for cancer drug Revlimid
Approved for use in patients with rare blood disorder
Alexion begins work on new global headquarters
Rare diseases drug company will move to new US site in 2015
Novartis launches European advanced breast cancer campaign
Virgo Health helps create audio/visual installation
J&J acquires oncology candidate in $1bn Aragon buy
ARN-509 is in phase II development for castration resistant prostate cancer
Men's oesophageal cancer risk "triple that of women"
New data from Cancer Research UK shines slight on 'quiet epidemic'
AstraZeneca picks location for global HQ and research base
Decides on the Cambridge Biomedical Campus in UK
Elotuzumab on track for multiple myeloma
BMS and AbbVie present phase II results at European Haematology Association meeting
New data backs J&J’s ibrutinib efficacy in B cell cancers
Phase II results showcased at European Hematology Association meeting
AstraZeneca and NGM form diabetes/ obesity partnership
Will use MedImmune arm to develop treatments that target gastrointestinal hormones
The future of HTA harmonisation in Europe
The variety and variability of European health technology assessment criteria have created a challenging environment for pharma and a need for much greater harmonisation
-
Carving an identity through customer-focused innovationBuilding pharma brands driven by customer-focused innovation will enable companies to differentiate their products in a crowded marketplace
-
Talking about a successful mergerHow communications can support effective mergers and acquisitions outcomes
-
Jakavi shows long-term survival benefit in myelofibrosisTrial demonstrates Novartis’ blood cancer drug cut risk of death by half over three years
-
UK launch for Pfizer's long-acting contraceptive injection Sayana
Becomes first contraceptive of its kind to reach the UK market
-
BMS partners with Simcere to market arthritis drug Orencia SC in ChinaBuilds on existing cancer/ cholesterol alliance between pharma companies
-
Roche's Avastin gains Japanese approval for brain cancerMarks drug's first approval to treat newly diagnosed glioblastoma
-
US charity calls for release of diabetes drug dataAmerican Diabetes Association demands review of incretin-based medicines linked to pancreatic cancer
-
FDA clears Amgen's Xgeva for rare bone conditionUS approval provides alternative to surgery for use in giant cell tumour of the bone
-
Partial victory for biotech sector after gene patent rulingUS Supreme Court decides genes can be patented, if synthetically produced
Latest appointments
-
Former UK health secretary joins Bupa boardPatricia Hewitt will serve private health firm as non-executive director
-
Former Novartis president joins Qu BiologicsRobert Pelzer is appointed board member at immunotherapy specialists
-
ABPI appoints new director of commsCatherine Meaden was previously head of policy and public affairs at the body
-
Icon appoints Dr Neil McCullough to senior compliance roleHe joins the clinical research organisation from PPD
-
Summit appoints Pfizer/Bayer veteran as CMODavid Roblin to lead development of therapies for Duchenne muscular dystrophy and C.difficile
Featured jobs
- Head of Commercial Training Strategy (m/ f)
- On application
- Marketing Manager - Pharmaceuticals, Northern UK
- Excellent Salary & Benefits
- UK Marketing Director
- 80,000 to 100,000 per annum
- Medical Writer / Editor – LONDON
- DOE
Subscribe to our email news alerts
- Celgene wins expanded EU approval for cancer drug Revlimid
- Alexion begins work on new global headquarters
- Former UK health secretary joins Bupa board
- Novartis launches European advanced breast cancer campaign
- J&J acquires oncology candidate in $1bn Aragon buy
- Men's oesophageal cancer risk "triple that of women"
PMHub
Add my companyBlue Latitude
Strategic Marketing Consultancy offering Intelligence, Insight and Imagination.
We are healthcare and Pharma specialists working for 9 of the World's top 20 ...
Latest intelligence
- What IF (Indigenus Forum) Meeting Report
- IFs (Indigenus Forums) are a series of invite-only events hosted by Indigenus agencies that bring top thought leaders together to help solve some of our industry’s most pressing challenges. ...
- Developing multichannel capability in Pharma
- Understanding your customers' needs is only half of the multichannel challenge; you must also have the business capability to deliver on your objectives. Find out how training could give your ...
- Deal Watch table for May 2013
- Table listing all the major pharma mergers, acquisitions and collaborations in the past month...
Quick links
